CDC Report Delay Raises Questions on Vaccine Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PFE?
Source: seekingalpha
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.220
Low
24.00
Averages
28.56
High
35.00
Current: 27.220
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer's 6.4% Dividend Yield Signals Potential Growth Amid Challenges
- Attractive Dividend Yield: Pfizer's current dividend yield stands at 6.4%, which, while appealing to income investors, may also signal potential sustainability issues, prompting investors to carefully assess future performance.
- Clinical Progress Potential: Pfizer launched 11 pivotal studies in 2025 and plans to initiate 20 more this year, with a robust phase 3 pipeline that could drive future growth, particularly with promising cancer drug PF'4404.
- Weight Management Therapy Outlook: Pfizer's MET097i weight management therapy excelled in phase 2 studies, showing potential for once-monthly dosing, which could differentiate it in the market and further boost company performance.
- Sustained Dividend Capability: Despite challenges such as patent expirations, Pfizer has consistently raised its dividends over the past five years, demonstrating its ability to maintain its dividend program during this transition period, appealing to investors seeking stable income.
See More
Analysis of Pfizer's Dividend Safety
- Attractive Dividend Yield: Pfizer's dividend yield stands at 6.4%, which, while appealing to income-seeking investors, may also signal potential risks of a payout cut, particularly given the company's poor stock performance.
- Stock Price Recovery: The stock has climbed 25% over the past year, indicating a rebound potential, especially as blue-chip stocks like Pfizer attract more investors amid current market volatility and geopolitical tensions.
- Promising R&D Pipeline: Pfizer launched 11 pivotal studies in 2025 and plans to introduce 20 more this year, with PF'4404, a novel cancer drug, poised to be a significant growth driver if approved.
- Sustained Dividend Capability: Despite facing challenges such as product exclusivity loss, Pfizer has consistently increased its dividends over the past five years, suggesting it can maintain its dividend program while launching new products to drive sales growth.
See More
Salesforce's Transformation and Challenges in the Age of AI
- Cost-Saving Strategy: Morgan DeBaun, CEO of Blavity, anticipates a shift from Salesforce's CRM platform to a more cost-efficient AI solution by early 2027, potentially saving 50% to 60%, highlighting the emphasis on cost-effectiveness in the AI era.
- Expectations for AI Features: DeBaun insists that Salesforce's AI capabilities should be included in the base offering rather than charged separately, indicating dissatisfaction with pricing strategies that could impact Salesforce's competitive position in the market.
- Market Reaction and Stock Volatility: Salesforce's stock has dropped over 35% in the past year, currently trading around $170, reflecting investor concerns about AI tools potentially disrupting traditional enterprise software, leading to a broader sell-off in software stocks.
- Future Outlook and Investment Confidence: Despite challenges, analysts remain bullish on Salesforce, with Citizens maintaining a buy rating and a $315 price target, demonstrating confidence in the company's ability to adapt to the evolving AI landscape.
See More
CDC Report Delay Raises Questions on Vaccine Efficacy
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
See More
Pfizer Announces Virtual 2026 Annual Shareholders Meeting
- Meeting Schedule: Pfizer has announced that its 2026 Annual Meeting of Shareholders will take place on April 23, 2026, at 9:00 a.m. EDT, allowing shareholders to register and access the meeting through a designated link, ensuring participation opportunities for all shareholders.
- Participation Guidelines: Shareholders must log into the virtual platform starting at 8:45 a.m. on the day of the meeting using a control number to ask questions or vote, a measure designed to ensure orderly proceedings and enhance interaction during the meeting.
- Question Submission Deadline: Shareholders can submit questions in advance of the meeting, with a deadline of April 21, 2026, at 5:00 p.m. EDT, providing an opportunity for shareholders to express concerns ahead of time and enhancing the transparency of the meeting.
- Webcast Replay Availability: A replay of the meeting will be available on Pfizer's website within 24 hours after the live event and accessible for up to one year, ensuring that shareholders who cannot attend in real-time can still access the meeting content, thereby improving information accessibility.
See More
PFIZER: BOFA GLOBAL RESEARCH LOWERS PRICE TARGET TO $26 FROM $27
- Price Adjustment: Pfizer has reduced the price of its BofA Global Research objective from $27 to $26.
- Market Impact: This price cut may influence market perceptions and investor strategies regarding Pfizer's financial outlook.
See More
Pfizer's 6.4% Dividend Yield Signals Potential Growth Amid Challenges
- Attractive Dividend Yield: Pfizer's current dividend yield stands at 6.4%, which, while appealing to income investors, may also signal potential sustainability issues, prompting investors to carefully assess future performance.
- Clinical Progress Potential: Pfizer launched 11 pivotal studies in 2025 and plans to initiate 20 more this year, with a robust phase 3 pipeline that could drive future growth, particularly with promising cancer drug PF'4404.
- Weight Management Therapy Outlook: Pfizer's MET097i weight management therapy excelled in phase 2 studies, showing potential for once-monthly dosing, which could differentiate it in the market and further boost company performance.
- Sustained Dividend Capability: Despite challenges such as patent expirations, Pfizer has consistently raised its dividends over the past five years, demonstrating its ability to maintain its dividend program during this transition period, appealing to investors seeking stable income.
See More
Analysis of Pfizer's Dividend Safety
- Attractive Dividend Yield: Pfizer's dividend yield stands at 6.4%, which, while appealing to income-seeking investors, may also signal potential risks of a payout cut, particularly given the company's poor stock performance.
- Stock Price Recovery: The stock has climbed 25% over the past year, indicating a rebound potential, especially as blue-chip stocks like Pfizer attract more investors amid current market volatility and geopolitical tensions.
- Promising R&D Pipeline: Pfizer launched 11 pivotal studies in 2025 and plans to introduce 20 more this year, with PF'4404, a novel cancer drug, poised to be a significant growth driver if approved.
- Sustained Dividend Capability: Despite facing challenges such as product exclusivity loss, Pfizer has consistently increased its dividends over the past five years, suggesting it can maintain its dividend program while launching new products to drive sales growth.
See More
Salesforce's Transformation and Challenges in the Age of AI
- Cost-Saving Strategy: Morgan DeBaun, CEO of Blavity, anticipates a shift from Salesforce's CRM platform to a more cost-efficient AI solution by early 2027, potentially saving 50% to 60%, highlighting the emphasis on cost-effectiveness in the AI era.
- Expectations for AI Features: DeBaun insists that Salesforce's AI capabilities should be included in the base offering rather than charged separately, indicating dissatisfaction with pricing strategies that could impact Salesforce's competitive position in the market.
- Market Reaction and Stock Volatility: Salesforce's stock has dropped over 35% in the past year, currently trading around $170, reflecting investor concerns about AI tools potentially disrupting traditional enterprise software, leading to a broader sell-off in software stocks.
- Future Outlook and Investment Confidence: Despite challenges, analysts remain bullish on Salesforce, with Citizens maintaining a buy rating and a $315 price target, demonstrating confidence in the company's ability to adapt to the evolving AI landscape.
See More
CDC Report Delay Raises Questions on Vaccine Efficacy
- Vaccine Efficacy Report Delayed: CDC's Jay Bhattacharya has postponed the publication of a report originally scheduled for March 19, which indicated that COVID vaccines could reduce the risk of ER visits and hospitalizations by nearly 50% in healthy adults, raising concerns about vaccine efficacy.
- Methodology Controversy: The study utilized a 'test-negative design' based on data from healthy adults receiving the 2025-2026 vaccine, showing a 50% and 55% reduction in ER visits and hospitalizations, respectively; however, Bhattacharya's concerns about the methodology may undermine public confidence in vaccines.
- Political Interference Concerns: A former CDC official suggested that the vaccine benefits are being downplayed due to the stance of HHS Secretary RFK Jr., who has pushed for restrictions on vaccine availability, potentially affecting the CDC's research publication and public health policy.
- Leadership Review Norm: An HHS spokesperson noted that it is routine for CDC leadership to review and flag concerns regarding study methodologies before publication, highlighting the complex interplay between science and politics in vaccine research dissemination.
See More
Pfizer Announces Virtual 2026 Annual Shareholders Meeting
- Meeting Schedule: Pfizer has announced that its 2026 Annual Meeting of Shareholders will take place on April 23, 2026, at 9:00 a.m. EDT, allowing shareholders to register and access the meeting through a designated link, ensuring participation opportunities for all shareholders.
- Participation Guidelines: Shareholders must log into the virtual platform starting at 8:45 a.m. on the day of the meeting using a control number to ask questions or vote, a measure designed to ensure orderly proceedings and enhance interaction during the meeting.
- Question Submission Deadline: Shareholders can submit questions in advance of the meeting, with a deadline of April 21, 2026, at 5:00 p.m. EDT, providing an opportunity for shareholders to express concerns ahead of time and enhancing the transparency of the meeting.
- Webcast Replay Availability: A replay of the meeting will be available on Pfizer's website within 24 hours after the live event and accessible for up to one year, ensuring that shareholders who cannot attend in real-time can still access the meeting content, thereby improving information accessibility.
See More
PFIZER: BOFA GLOBAL RESEARCH LOWERS PRICE TARGET TO $26 FROM $27
- Price Adjustment: Pfizer has reduced the price of its BofA Global Research objective from $27 to $26.
- Market Impact: This price cut may influence market perceptions and investor strategies regarding Pfizer's financial outlook.
See More
